Zobrazeno 51 - 60
of 150
pro vyhledávání: '"Alexey Aleshin"'
Autor:
Antony Tin, Lillian L. Siu, Nickolas Attanasio, David P. Goldstein, Tina Shek, Bayardo Perez-Ordonez, J. Javier Díaz-Mejía, Ronald Shazer, Anna Spreafico, Douglas B. Chepeha, Ben X Wang, Ilan Weinreb, Hirak Der-Torossian, Andrew Hope, Aaron R. Hansen, Daniel Vilarim Araujo, Qingyan Au, Amy Prawira, John R. de Almeida, Alexey Aleshin, Jordan Feeney, Marc Oliva, Peter Olson, Stephen M. Smith, Jonathan C. Irish, Jeff Bruce, Anthony Fortuna, Himanshu Sethi, Isan Chen, Trevor J. Pugh, Dax Torti, Scott V. Bratman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundSitravatinib, a tyrosine kinase inhibitor that targets TYRO3, AXL, MERTK and the VEGF receptor family, is predicted to increase the M1 to M2-polarized tumor-associated macrophages ratio in the tumor microenvironment and have synergistic ant
Autor:
Angel Rodriguez, Meenakshi Malhotra, Shifra Krinshpun, Sascha Ellers, Nicole Hook, S Sawyer, Solomon Moshkevich, Michelle Munro, Alexey Aleshin, Jacob Wulff, Jessica Guilford, Pashtoon Murtaza Kasi, Axel Grothey, Scott Kopetz, Paul Billings, Allyson Koyen Malashevich
Publikováno v:
BMJ Open
BMJ Open, Vol 11, Iss 9 (2021)
BMJ Open, Vol 11, Iss 9 (2021)
IntroductionColorectal cancer (CRC) is a highly prevalent disease, wherein, ~30%–40% of patients with CRC relapse postresection. In some patients with CRC, adjuvant chemotherapy can help delay recurrence or be curative. However, current biomarkers
Autor:
Tomoko Akaike, Naomi So, Daniel S. Hippe, Lindsay Gunnell, Coley Doolittle- Amieva, Kristina Lachance, Evan Hall, Shailender Bhatia, Alec Eschholz, Richa Rathore, Nicole Hook, Kathryn Baker, Angel Rodriguez, Andrew Ecklund, Alexey Aleshin, Paul Nghiem, Lisa C. Zaba
Publikováno v:
Journal of Investigative Dermatology. 142:2837
Autor:
Luciana Molinero, Derrick Renner, Hsin-Ta Wu, Nina Qi, Rajesh Patel, Ching-Wei Chang, Himanshu Sethi, Alexey Aleshin, Carlos Bais, David Cameron
Publikováno v:
Cancer Research. 82:2796-2796
Background: Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype, even in early stages. Evidence of molecular residual disease (MRD), after treatment with curative intent (surgery, chemotherapy), predating macroscopic rec
Autor:
Mark Jesus Mendoza Magbanua, Lamorna Brown Swigart, Derrick Renner, Svetlana Shchegrova, Gillian L. Hirst, Christina Yau, Denise M. Wolf, Hsin-Ta Wu, Ekaterina Kalashnikova, Amy L. Delson, A. Jo Chien, Debu Tripathy, Smita Asare, Raheleh Salari, Angel Rodriguez, Bernhard Zimmermann, Himanshu Sethi, Alexey Aleshin, Paul Billings, Rita Nanda, Hope S. Rugo, Laura J. Esserman, Minetta C. Liu, Angela DeMichele, Laura van 't Veer
Publikováno v:
Cancer Research. 82:LB111-LB111
Background: We compared the predictive and prognostic value of ctDNA dynamics in high-risk hormone receptor-positive/HER2-negative (HR+/HER2-) and triple negative breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAC) enrolled in the I-SPY 2 t
Autor:
Emily S. Lebow, Yonina R. Murciano-Goroff, Justin Jee, Ekaterina Kalashnikova, Jordan Feeney, Himanshu Sethi, Alexey Aleshin, Mark G. Kris, Jamie E. Chaft, Charles M. Rudin, David Randolph Jones, Pedram Razavi, Jorge S. Reis-Filho, Daniel Richard Gomez, Daphna Y. Gelblum, Narek Shaverdian, James M. Isbell, Bob T. Li, Andreas Rimner
Publikováno v:
Journal of Clinical Oncology. 40:8540-8540
8540 Background: The standard of care for patients with inoperable early stage or locally advanced NSCLC is definitive stereotactic body radiotherapy (SBRT) or conventional radiation therapy (RT) with systemic therapy. Circulating tumor DNA (ctDNA) t
Autor:
Christine B. Peterson, Ekaterina Kalashnikova, Jordan Feeney, Allyson Koyen Malashevich, Himanshu Sethi, Alexey Aleshin, Eric Jonasch
Publikováno v:
Journal of Clinical Oncology. 40:4525-4525
4525 Background: Approximately 30% of renal cell carcinoma (RCC) cases present as stage IV at the time of diagnosis. Metastatic RCC (mRCC) is associated with poor outcomes, with a five-year survival rate below 50%. Tools to evaluate the efficacy of n
Autor:
Jason Russell Williams, Kassondra Grzankowski, Kayla Castaneda, Jose Salvador Saldivar, Concepcion Diaz-Arrastia, Georges Azzi, Hemant Sindhu, Young Kwang Chae, Ekaterina Kalashnikova, Brittany Nicosia, Shilpa Tekula, Giby V. George, Meenakshi Malhotra, Adam ElNaggar, Alexey Aleshin
Publikováno v:
Journal of Clinical Oncology. 40:e17501-e17501
e17501 Background: The role of immunotherapy in gynecologic malignancies continues to evolve. Use of immune checkpoint blockade (ICB) agents have consistently demonstrated less than a 15% response rate in ovarian, cervical, and subsets of endometrial
Autor:
Sarah Tomassetti, Yazeed Samara, Katie LaBarbera, Xin Qing, Richa Rathore, Alexey Aleshin, Laron McPhaul
Publikováno v:
Journal of Clinical Oncology. 40:e19552-e19552
e19552 Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. With upfront treatment, 40% of patients relapse. Currently, treatment response and surveillance are monitored using positron emission tomography/computerize
Autor:
Thomas J. George, Greg Yothers, Anuradha Krishnamurthy, Saima Sharif, Caio Max Sao Pedro Rocha Lima, Howard S. Hochster, Jesus C. Fabregas, Alok A. Khorana, Martin Gutierrez, Moses S. Raj, Ana Acuna Villaorduna, Carmen Joseph Allegra, Samuel A. Jacobs, Alexey Aleshin, Stacie Ittershagen, Shannon Leigh Huggins-Puhalla, Norman Wolmark
Publikováno v:
Journal of Clinical Oncology. 40:TPS3642-TPS3642
TPS3642 Background: Detection of circulating tumor DNA (ctDNA) in patients (pts) following surgery is indicative of presence of minimal/molecular residual disease (MRD) and confers a near-certain risk of disease recurrence. Therapeutic strategies to